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Intravenous IgG (IVIg) contains polyclonal immunoglobulin G (IgG) from thousands of
donors. It is administered at a low dose at regular intervals as antibody replacement
therapy and at a higher dose as immunomodulatory treatment in various auto-immune
or auto-inflammatory diseases. The working mechanism of immunomodulation is not well
understood. Many different explanations have been given. During the last decade, we have
focused on classical antibody binding via the Fc-domain of the IgG molecules to the com-
mon IgG receptors, i.e. the Fcγ receptors (FcγRs). Variation in the genes encoding human
FcγRs determines function as well as expression among immune cells. As described here,
NK cells and myeloid cells, including macrophages, can express different FcγR variants,
depending on the individual’s genotype, copy number variation (CNV), and promoter poly-
morphisms. B-cells seem to only express the single inhibitory receptor. Although these
inhibitory FcγRIIb receptors are also expressed by monocytes, macrophages, and only
rarely by NK cells or neutrophils, their presence is unlikely to explain the immunomodu-
latory capacity of IVIg, nor does the sialylation of IgG. Direct IVIg effects at the level of
the activating FcγRs, including the more recently described FcγRIIc, deserve renewed
attention to describe IVIg-related immunomodulation.
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INTRODUCTION
Intravenous IgG (IVIg) is a blood product containing polyclonal
immunoglobulin G (IgG) isolated and pooled from thousands of
donors. IVIg is mainly used in two clinical situations. It is admin-
istered at a low dose at regular intervals as antibody replacement
therapy in primary immunodeficiencies such as agammaglob-
ulinemia and common variable immunodeficiency (CVID), or
acquired immunodeficiencies where IgG plasma concentrations
have become very low. In this context, suppletion essentially func-
tions to provide the recipient with a repertoire of protective
antibodies against a range of predominantly bacterial infections.
On the other hand, IVIg can also be used at a high dose
as an immunomodulatory treatment in auto-immune or auto-
inflammatory diseases, of which a handful are FDA- and EMEA-
approved, including Kawasaki disease and immune thrombocy-
topenia (ITP). In this respect, IgG administration has also been
used off-label for a growing number of additional diseases, includ-
ing hematologic, dermatologic, and neuromuscular disorders. A
list of indications for treatment with IVIg is provided in Table 1.
Many but certainly not all of these diseases involve (auto)-antibody
responses, questioning the actual working mechanism of IVIg
under conditions where auto-antibodies have not yet been shown
to be involved.
Even though IVIg is widely used and has proven to be an
effective treatment for many diseases, the exact immunomodu-
latory mechanism(s) have remained elusive. Several mechanisms
by which IVIg may exert its anti-inflammatory effects have been
proposed over the past decades (1), listed in Table 2. These mech-
anisms are not necessarily mutually exclusive, and may act in
concert to modulate the immune system. Furthermore, different
mechanisms may be at work in the different diseases for which
IVIg is administered. In this review, we describe the different the-
ories that may explain the immunomodulatory effect of IVIg, with
a special interest in the actions of IVIg in ITP, being the first disease
for which the usefulness of IVIg as an immune-modulatory agent
was discovered (2).
Many of the theories aiming to explain the working mechanism
involve Fc gamma receptors (FcγRs), which are the main recep-
tors for IgG and therefore very likely to be involved in the working
mechanisms of IVIg. Therefore, we start with an introduction of
human FcγRs, followed by a description of the potential work-
ing mechanisms of IVIg, discussing how IVIg can shape immune
responses by altering or interfering with FcγR expression and
function.
Fc GAMMA RECEPTORS
FcγRs are receptors for (IgG), the most abundant of five classes
of Ig. IgG consists of a Fab (fragment, antigen-binding) region,
which determines specificity to specific antigens, and a constant
region, which is the Fc (fragment, crystallizable) region, which
(among other functions) mediates the effector functions of IgG,
including the interactions with their major receptors, the FcγRs.
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Table 1 | Overview of indications for treatment with IVIg.
IVIg as substitution therapy
Primary immunodeficiency disease
Chronic lymphocytic leukemia
Pediatric HIV infection
Common variable immunodeficiency
IVIg as immunomodulatory therapy
Inflammatory disorders
Kawasaki’s disease
Transplantation
Kidney transplantation involving a recipient with a high antibody titer or
an ABO-incompatible donor
Allogeneic bone marrow transplantation
Graft-versus-host disease
Hematologic disorders
Immune thrombocytopenia
Auto-immune hemolytic anemia
Auto-immune neutropenia
HIV-associated thrombocytopenia
Neonatal alloimmune thrombocytopenia
Severe anemia associated with parvovirus B19
Dermatologic disorders
Bullous pemphigoid
Epidermolysis bullosa acquisita
Mucous-membrane (cicatricial) pemphigoid
Pemphigus vulgaris
Toxic epidermal necrolysis or Stevens–Johnson syndrome
Neuromuscular disorders
Birdshot retinopathy
Chronic inflammatory demyelinating polyneuropathy
Multifocal motor neuropathy
Guillain–Barré syndrome
Lambert–Eaton myasthenic syndrome
Myasthenia gravis
Opsoclonus–myoclonus
Polyradiculoneuropathy
Refractory dermatomyositis
Refractory polymyositis
Relapsing–remitting multiple sclerosis
These receptors are found on almost all immune cells (Table 3)
and, upon binding of IgG, mediate a wide range of cellular
responses, such as phagocytosis of IgG-opsonized microorganisms
or immune complexes, antibody-dependent cellular cytotoxicity
(ADCC), activation of the NADPH oxidase, and the release of
cytokines.
Importantly, as compared to many innate pattern recognition
receptors, human FcγRs are quite different from their murine
counterparts in the sense that no clear orthologs can be assigned.
As a result, human and murine FcγRs that share nomenclature
and CD numbers actually have quite different protein structures,
expression patterns, and Ig binding affinities (3). Thus, functional
studies on mouse FcγRs can only provide very limited informa-
tion for understanding the contributions of individual FcγRs to
human disease.
Table 2 | Potential immunomodulatory mechanisms of IVIg.
Fc-mediated mechanisms
1. Blockade of activating FcγR by saturation via high-dosed IVIg making
them less available for auto-antibodies in oligo- or polymeric complex with
their (auto)antigen
2. Upregulation of the inhibitory FcγRIIb by sialylated IgG Fc
3. Increased clearance of pathogenic antibodies by saturation of the
neonatal FcR (FcRn)
4. Tipping the cellular balance from pro- to anti-inflammatory reactivity by
modulating dendritic cells (DCs)
5. Reducing responses to IFN
6. Inhibition of the complement cascade by sequestering complement
away from the deposited auto-antibodies
Fab-mediated mechanisms
7. Neutralization of various agents (similar to mAb), including chemokines,
inflammatory cytokines, and apoptosis-inducing molecules, including FasL
8. Neutralization of auto-antibodies by anti-idiotype Abs – often claimed but
never proven to effectively explain the anti-inflammatory potential
STRUCTURE, SIGNALING, AND EXPRESSION
Based on their affinity for monomeric IgG, FcγRs can be divided
into the high-affinity FcγRI and the low-affinity FcγRII and
FcγRIII (Figure 1). Signaling by FcγR is mediated by immunore-
ceptor tyrosine-based activating (ITAM) or inhibitory (ITIM)
motifs that are present either in the cytoplasmic tail of the receptor
itself or in non-covalently associated signaling adaptor proteins,
such as the common γ-chain (FcRγ; see below). Aggregation of
activating FcγR, i.e., those containing or associated with ITAMs,
by binding of multivalent ligands, such as an opsonized pathogen
or cancer cell, results in the phosphorylation of ITAM tyrosine
residues by Src family protein tyrosine kinases (PTKs), and ulti-
mately leads to activation of cellular responses (10). Aggregation of
inhibitory FcγR, i.e., those containing ITIMs, also results in phos-
phorylation of tyrosine residues by Src family PTKs. In contrast
to ITAMs, phosphorylated ITIMs serve as binding sites for phos-
photyrosine phosphatases (PTPs), which dephosphorylate other
proteins resulting in inhibition of activating pathways (11).
FcγRI (CD64) is a 72 kDa protein that has three extracellular
(EC) Ig-like domains, involved in binding of IgG, a transmem-
brane (TM) domain and a short intracellular (IC) domain of 61
amino acids. The TM domain associates with the FcRγ-chain,
an adaptor protein containing an ITAM, to induce signaling and
maintain stable expression (12). FcγRI is constitutively expressed
by monocytes, macrophages, and dendritic cells and its expression
can be induced on neutrophils by stimulation with IFN-γ and/or
G-CSF (13, 14). Although there are three genes with various tran-
scripts (15, 16), it is generally believed that only one, the FCGR1A
transcript, results in the expression of the classical FcγRIa (CD64).
FcγRII (CD32) is actually a collection of three highly homol-
ogous proteins, known as FcγRIIa, -b, and -c that all have a
molecular mass of ~40 kDa. Their genes are located in one gene
cluster at chromosome 1q23.3 (Figure 2). In contrast to FcγRI,
the FcγRII proteins have only two IgG binding EC domains. On
the other hand, the much larger intracellular domains of FcγRIIa,
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Table 3 | Expression of FcγRs on different cell types.
FcγRI FcγRIIa FcγRIIb FcγRIIc FcγRIIIa FcγRIIIb
B-cells − − + − − −
T cells − − − − − −
NK cells − − Genotype-dependenta Genotype-dependentb + −
Dendritic cells + + + Genotype-dependent?b − −
Macrophages + + + Genotype-dependentb + −
Monocytes + + Subsets Genotype-dependentb Subsets −
Neutrophils Induced + Genotype-dependentc Genotype-dependentb − +
Eosinophils Inducedd + − − − Inducedd
Platelets − + − − − −
Expression of FcγRs on different cell types, derived from our own data [Ref. (4–6), Figure 3, data not shown] as well as review of the literature (3).
aExpression of FcγRIIb occurs in NK cells in individuals with a deletion of CNR1 (Figure 2) (4).
bExpression of FcγRIIc is dependent on SNPs in exon3 and intron7 of the FCGR2C gene, which in most individuals is a non-expressed pseudogene (4, 5).
cExpression of FcγRIIb on neutrophils strongly correlates with SNPs in the promoter of the FCGR2B gene [promoter haplotype 2B.4 (7),Tsang-a-Sjoe et al., submitted)].
dAlthough FcγRI and FcγRIIIb are definitely absent from eosinophils in the resting state, and are often regarded not expressed by these cells (3), some reports have
described inducible expression in vitro for FcγRI and FcγRIIIb (8) and also in vivo for FcγRIII (9).
FIGURE 1 | Nomenclature and structure of human FcγRs. All human
FcγRs are transmembrane proteins, except the GPI-linked FcγRIIIb. The
high-affinity FcγRI contains three extracellular (EC) domains (gray ellipses),
the low-affinity FcγRs contain two. All isoforms of FcγRII contain either an
immunoreceptor tyrosine-based activating (ITAM, white boxes) or inhibitory
(ITIM, black box) motif in their α-chain. FcγRI and FcγRIIIa associate with
ITAM-containing adaptor proteins such as the Fc receptor common gamma
chain (indicated by “γ”) and the CD3 ζ-chain (indicated by “ζ”).
-b, and -c harbor intrinsic signaling motifs. In contrast to the
activating FcγRIIa and -c, FcγRIIb contains an immunoreceptor
tyrosine-based inhibitory motif (ITIM) (17). As no other FcγR
contains or associates with proteins containing ITIMs, FcγRIIb is
the only inhibitory FcγR (18).
FcγRIIa is the most widely expressed isoform of FcγRII and
is found on monocytes, macrophages, dendritic cells, neutrophils
and platelets.
FcγRIIb is highly expressed on B-cells, where it constitutes the
only surface-expressed FcγR. FcγRIIb is also expressed, albeit at
much lower levels, on a subset of monocytes, on macrophages,
and on dendritic cells. Expression of FcγRIIb can also be detected
on neutrophils and NK cells, but only in individuals with certain
genotypes [Ref. (4), Tsang-a-Sjoe et al., submitted].
FcγRIIc has long been considered not to be expressed at all,
as its gene (FCGR2C) was thought to be a pseudogene (19, 20),
and therefore, relatively little was known about the expression
pattern of this receptor. In 1998, FcγRIIc was first found on NK
cells of individuals with a particular haplotype of the receptor
(21), but we now know that – apart from NK cells – it can also
be expressed on neutrophils and monocytes in the individuals
with the appropriate genotype (4, 5) (Figure 3A). As this acti-
vating FcγRIIc is expressed on circulating monocytes of some
individuals, it may be expected that expression also occurs on
(monocyte-derived) macrophages of these same individuals, but
this has not been reported to date. Here, we show for the first time
that monocyte-derived macrophages do indeed express FcγRIIc,
at least when cultured in the presence of M-CSF (M2 phenotype),
as shown by flowcytometry stainings with MoAb 2B6, which rec-
ognizes both FcγRIIb and FcγRIIc (Figure 3C). Although these
data are difficult to interpret because of the (varying) presence
of FcγRIIb on these cells, we can assume the mean difference in
MFI between FCGR2C-ORF and FCGR2C-Stop donors to derive
from FcγRIIc. Expression of FcγRIIc specifically was confirmed
by qPCR of FCGR2C mRNA and a specific immunoprecipitation
using a combination of MoAb 2B6 and a polyclonal antibody that
binds FcγRIIc but not FcγRIIb (Figure 3C). Monocyte-derived
macrophages differentiated with GM-CSF (M1 phenotype) do not
seem to express FcγRIIc based on flowcytometry, although also in
these cells, low levels of FCGR2C mRNA could be detected, there-
fore expression of FcγRIIc cannot be ruled out and may occur
in later stages of differentiation of M1 macrophages. Recently, it
was proposed that FcγRIIc can also be expressed on B-cells (22).
However, evidence of expression of this receptor on B-cells on our
own cohort of healthy donors was not confirmed on B-cells, irre-
spective their naïve or memory phenotype (Figure 3B; data not
shown).
FcγRIII (CD16), similarly to FcγRII, actually represents a col-
lection of two genes, expressed within the gene cluster at chro-
mosome 1q23.3, each encoding proteins with two EC Ig-like
domains (Figures 1 and 2). Due to differences in glycosylation,
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FIGURE 2 | Overview of the low-affinity FcγR gene cluster and the corresponding CNV. Three combinations of FcγR genes have been shown to occur in
duplication/deletion. Black lines indicate which genes are involved in CNV.
their molecular masses are in the range of 50–80 kDa. FcγRIIIa
is similar to FcγRI in its TM and IC domains. In monocytes and
macrophages, this receptor associates with the FcRγ-chain, while
in NK cells it associates with the CD3 ζ-chain to induce signal-
ing (26–28). In contrast to FcγRI, association with these adaptor
proteins is not only essential for maintaining stable expression but
also for targeting the receptor to the cell membrane (28).
FcγRIIIb is a GPI-anchored protein, expressed only on neu-
trophils and eosinophils. As it does not have a TM domain, it
cannot associate with FcRγ or the ζ-chain. Nonetheless, FcγRIIIb
has been suggested to induce signaling, although the exact mech-
anism(s) is still unclear (29, 30), and current believe is that it
functions mainly as a decoy receptor (31).
Recently, it has been proposed that a totally different class of
receptors, the C-type lectins, may also bind the Fc-region of IVIg
(32), and such receptors were termed “type II Fc receptors.” In
humans, DC-SIGN was proposed to bind IgG with a sialic acid
sugar moiety at the Asn297 N-linked glycosylation site of IgG.
However, this interaction could not be reproduced by another
group (33), which found no binding at all of IgG-Fc regions to
DC-SIGN, regardless of the sialylation status. Therefore, with evi-
dence for the interaction of IgG-Fc and DC-SIGN being currently
marginal and not broadly supported in the literature, in our opin-
ion, it remains to be seen whether DC-SIGN should indeed be
classified as a true IgG-Fc receptor.
GENETIC VARIATION IN FcγR: POLYMORPHISMS
The genes encoding the classical FcγRs are highly polymorphic
and functionally relevant genetic variations have been described
for all low-affinity FcγRs (Table 4).
In FCGR2A, encoding for FcγRIIa, a single nucleotide polymor-
phism (SNP) was first noticed, which results in either a histidine
or an arginine at position 131 (H131R) in the IgG binding domain
(EC2) (34). FcγRIIa-H131 has a higher binding affinity for IgG1
and especially IgG2, as compared to FcγRIIa-R131, but binding
to IgG3 and IgG4 is similar for both variants (38). Function-
ally, mononuclear cells from FcγRIIa-131HH individuals produce
more IL-1beta when stimulated with IgG2 than FcγRIIa-131HR
and -131RR individuals (39). Similarly, neutrophils from individ-
uals homozygous for H131 (FcγRIIa-131HH) have been shown
to have increased phagocytosis and degranulation in response to
serum-opsonized bacteria and increased rosette formation and
phagocytosis in presence of IgG3 anti-D sensitized erythrocytes
when compared to FcγRIIa-131RR individuals (36, 40).
FCGR2B also exists in two allelic variants, encoding for FcγRIIb
containing either an isoleucine or a threonine at position 232
in the TM domain (35). As this SNP (I232T) does not affect
the IgG-binding EC domains, it has no influence on the bind-
ing affinity. However, its localization at the TM domain results in
differences in downstream signaling and subsequent inhibition of
FcγRI signaling in macrophages and BCR signaling in B-cells. In
particular, I232 provides stronger inhibitory signaling than T232,
and this is caused by the exclusion from lipid rafts of FcγRIIb-T232
(41, 42). As FcγRIIb is the only inhibitory FcγR, it has a central
role in the regulation of immune responses. The loss-of-function
FcγRIIb-T232 has been linked to susceptibility and/or severity of
several auto-immune diseases, particularly SLE (43–45), and also
in rheumatoid arthritis (RA) (46) and ITP (47).
Inter-individual variation in FcγRIIb is also found in expres-
sion patterns and levels. Similar to the I232T SNP, the important
immune-regulatory role for FcγRIIb is also reflected in the obser-
vations of aberrant expression levels of FcγRIIb in SLE, RA, ITP,
and chronic inflammatory demyelinating polyneuropathy (7, 48–
51). As a result of a deletion in the FCGR locus that includes
FCGR2C, FCGR3B and is called CNR1, FcγRIIb can surprisingly
also be expressed on the surface of NK cells, where it is capa-
ble to inhibit killing of target cells in ADCC (4). Expression of
FcγRIIb in other cells is hardly affected by this deletion. Fur-
thermore, two SNPs in the proximal promoter of FCGR2B and
FCGR2C, a guanine or cytosine at position −386 and a thymine
or adenine at position −120, form four haplotypes of which one
(−386G,−120A; 2B.3) has never been found in any individual thus
far. In case of FCGR2B, the wildtype promoter (−386G, −120T;
2B.1) has a lower transcriptional activity than one of the other
haplotypes (−386C, −120A; 2B.4) [Ref. (51); Tsang-a-Sjoe et al.,
submitted].
In case of FCGR2C, only the wildtype and one other promoter
haplotype (−386C, −120T; 2B.2) are found. Moreover, the 2B.2
haplotype is linked to another polymorphism in FCGR2C (5).
This other polymorphism, a SNP in exon 3, determines whether
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FIGURE 3 | FcγRIIc expression on various cell types in healthy human subjects.
(Continued)
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FIGURE 3 | Continued
(A) Expression of FcγRIIc and FcγRIIb on circulating leukocytes. Figure
adapted from van der Heijden et al. (4), now including measurements from
additional individuals. MoAb 2B6 recognizes an extracellular epitope of both
FcγRIIb and FcγRIIc, but since FCGR2C -Stop individuals cannot express
FcγRIIc, the difference in MFI between FCGR2C -Stop and FCGR2C -ORF
individuals can be assumed to derive from expression of FcγRIIc.
FCGR2C -Stop (individuals with zero copies of FCGR2C -ORF) n=105;
FCGR2C -ORF (including individuals with one and two copies of
FCGR2C -ORF) n=31. Means+SEM are shown. (B) Detailed analysis of
MoAb 2B6 staining on circulating B-cells, showing individual measurements,
reveals no evidence of expression of FcγRIIc on B-cells. FCGR2C -Stop
n=105; FCGR2C -ORF(1x), individuals with one copy of FCGR2C -ORF, n=24;
FCGR2C -ORF(2x), individuals with two copies of FCGR2C -ORF, n= 7.
(C) Expression of FcγRIIc on macrophages. Upper panel: MoAb 2B6 staining
on monocyte-derived macrophages cultured for 9 days from 36 healthy
individuals, performed as previously described (79). FCGR2C -Stop: n=24;
FCGR2C -ORF, individuals with one (n=11) or two (n=1) copies of the
FCGR2C -ORF allele. Data are shown for M-CSF (left) and GM-CSF (right)
cultured macrophages. Lower left panel: detection of FCGR2C mRNA in
monocyte-derived macrophages cultured for 9 days. qPCR with
FCGR2C1-specific primers was performed as previously described (5), using
cDNA from M-CSF monocyte-derived macrophages as a calibration curve, as
described in (79). FCGR2C -ORF, individuals with 1 FCGR2C -ORF allele, n=3;
FCGR2C -Stop, individuals with zero copies of FCGR2C -ORF, n=4.
Means+SEM are shown. Lower right panel: immunoprecipitation of FcγRIIc
from M-CSF monocyte-derived macrophages confirms expression of FcγRIIc.
Experiment was performed essentially as described in Ref. (4), in this case
using MoAb 2B6 to capture FcγRIIc (and FcγRIIb), followed by a specific
staining for the intracellular part of FcγRIIc with a rabbit polyclonal antibody
against the cytoplasmic tail shared by FcγRIIc and FcγRIIa (25), in
macrophages from an individual with zero copies of FCGR2C -ORF (Stop), and
an individual with one copy of FCGR2C -ORF (ORF). Data are representative
of three independent experiments with different individuals.
For reasons of simplicity, in this figure, individuals with the non-classical
FCGR2C -ORF allele that is not expressed (4) [n=6 for (A,B), were grouped
with FCGR2C -stop individuals. Individuals with a deletion of CNR1 (FCGR2C
and FCGR3B genes], which leads to ectopic expression of FcγRIIb on NK
cells (4) (n=14), were left out of the analysis of NK cells in (A). Statistical
significance was tested by Mann–Whitney U test. ns (p>0.05); *p<0.05;
**p<0.01; ***p<0.001; ****p<0.0001. ∆ MFI: median fluorescence
intensity of MoAb 2B6 minus median fluorescence intensity of isotype
control. Some individuals were analyzed more than once at different time
points with similar results, means are shown for these individuals.
Table 4 | Functionally relevant genetic variation in FcγR.
Gene Type Variants Functional relevance
FCGR2A SNP H131, R131 H131 has a higher binding affinity for IgG1 and IgG2 than R131 (34)
FCGR2A Splice site mutation c.739+871A,
c.739+871G
c.739+871A>G leads to splice variant FcγRIIaexon6*, which shows increased cellular
activation
FCGR2B SNP I232, T232 I232 inhibits FcγRI as well as B-cell receptor signaling more strongly than T232 (35)
FCGR2B,
FCGR2C
Promoter haplotype 2B.1, 2B.2, 2B.3, 2B.4 2B.2 is linked with an ORF in FCGR2C (5).
2B.4 results in increased transcription of FCGR2B (7)
FCGR2C SNP Q13, Stop13 Q13 leads to an ORF in exon 3 and expression of FcγRIIc (21), when combined with
c.798+1G
FCGR2C Splice site mutation c.798+1G, c.798+1A c.798+1A leads to mis-splicing and lack of expression of FcγRIIc (4)
FCGR3A SNP V158, F158 V158 has a higher binding affinity for all human IgG isotypes than F158 (52)
FCGR3A CNV 1, 2, 3, or 4 copies Copy number relates to expression levels of FcγRIIIa and NK-cell IgG-mediated ADCC (24)
FCGR3B Polymorphic variants NA1, NA2, SH NA1 phagocytizes more efficiently than NA2 (40, 57)
FCGR3B CNV 0, 1, 2, 3, or 4 copies Copy number relates to expression levels of FcγRIIIb and the binding and uptake of IC’s
or not individuals can express FcγRIIc at all. This C>T mutation
results in either an open-reading frame (FCGR2C-ORF, allele fre-
quency ~10–15% in Caucasians) or a stop codon (FCGR2C-Stop)
(5). Although expression on NK cells is low, it has been shown to
be capable of inducing killing of target cells in a redirected ADCC
assay (5). Classically, ORF/Stop genotyping of individuals is done
based on this SNP alone. However, we have recently found that
some individuals carry splice site mutations in intron 7 that intro-
duce novel stop codons, leading to a loss of FcγRIIc expression (4),
and genotyping FCGR2C should include these novel mutations to
provide an accurate prediction for FcγRIIc expression.
The FcγRIIIa-encoding FCGR3A gene contains a SNP that
results in either a valine or a phenylalanine at position 158
(V158F), located in the second EC domain (52). FcγRIIIa-V158
has a higher binding affinity for all human IgG classes com-
pared to FcγRIIIa-F158 (38). In ADCC assays, NK cells from
FcγRIIIa-V158 donors show increased killing of target cells that
are opsonized with sub-saturating levels of Rituximab (53).
FcγRIIIb-encoding FCGR3B gene exists in three polymorphic
variant proteins, NA1, NA2, and SH, which are also known as
HNA-1a, -1b, and -1c, respectively (54, 55). FcγRIIIb-NA1 and
-NA2 nucleotide sequences differ at five positions [G>C at
nucleotide (nt) 141, C>T at nt 147, A>G at nt 227, G>A at
nt 277, and G>A at nt 349], with four predicted amino acid
differences (R36S, N65S, D82N, and V106I for NA1 and NA2,
respectively). As a consequence, the NA2 variant has two additional
N-linked glycosylation sites, compared to NA1. The SH variant is
identical to NA2 at the five positions that distinguish NA1 from
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NA2, but differs from both variants at one additional position
(C>A at nt 266), resulting in an A78D amino acid change that
predicts a change in the tertiary structure of the protein. Addi-
tional complexity is added by the discovery of rare individuals
carrying other mutations within this gene or different combi-
nations of these nucleotide polymorphisms (37, 56), indicating
that the NA1/NA2/SH typing is incomplete. While the binding
affinities for IgG1 and IgG3 appear similar between the three vari-
ants (38), neutrophils from FcγRIIIb-NA1NA1 individuals bind
and phagocytize IgG-opsonized bacteria and red blood cells more
efficiently than those from FcγRIIIb-NA1NA2 and -NA2NA2
individuals (40, 57).
GENE COPY NUMBER VARIATION
Besides being polymorphic, some of the low-affinity FCGR genes
are subject to gene copy number variation (CNV). Although
several large-scale studies on CNV have suggested that human
FCGR2A and FCGR2B are candidate genes for CNV (58–61), our
group has shown previously that this is not the case. In fact, CNV
in the FCGR locus is restricted to FCGR2C, FCGR3A, and FCGR3B
(24). It occurs in three different combinations: FCGR3A/FCGR2C
(two possibilities with slightly different borders to the CNV
region), and FCGR2C/FCGR3B (Figure 2).
Copy number variation translates into differences in expres-
sion levels of FcγRIIc (in case of FCGR2C-ORF), FcγRIIIa, and
FcγRIIIb, with more gene copies leading to a higher receptor
expression (and vice versa) (21, 62, 63). In case of FcγRIIIa, the
level of expression on NK cells is, at least for 1 versus 2 copies,
related to the level of killing of target cells in (redirected) ADCC
assays (24). Increased expression of FcγRIIIb leads to higher
binding and uptake of immune complexes (ICs) (64).
As is the case with polymorphic variants, CNV in FCGR genes is
associated with several auto-immune diseases. Our group has pre-
viously shown that FCGR2C-ORF predisposes for ITP. The SNP
in exon 3 causing an open-reading frame instead of a stop allele of
FCGR2C, results in the expression of FcγRIIc and thus behaves as
if it were CNV of FCGR2C-ORF. However, individuals can have an
increased CNV at this locus of three FCGR2C-Stop alleles without
increased risk since only the ORF allele was shown to predispose
to ITP (5).
Although we could not find an association with various dis-
ease cohorts (24), an increased copy number of FCGR3A has
been observed in anti-glomerular basement membrane antibody
disease (anti-GBM disease) (65).
In contrast, a low copy number of FCGR3B has been shown to
be a risk factor for SLE, even when linkage disequilibrium between
FCGR3B CNV and FcγR SNPs that have previously been shown
to be associated with SLE is taken into account (66–70). Similar
associations have been reported for Sjögren’s syndrome (67), sys-
temic sclerosis (71), and RA (72, 73), although other reports have
shown no association with RA (67, 74).
POTENTIAL WORKING MECHANISMS FOR THE
IMMUNOMODULATORY EFFECT OF IVIg
Potential mechanisms can be divided into two categories, being
dependent on either the Fc part or the Fab part of the IgG mole-
cule. For some indications, such as ITP, clinical studies with human
subjects have in fact already revealed what part of the IgG mole-
cule is effective, as preparations with only Fab fragments of IVIg
were not effective (75), whereas purified Fc fragments did have
a good clinical effect (76). Thus, we know that at least for ITP,
the immunomodulatory effect is Fc-mediated, although this may
be different for other indications. Here, we focus most on Fc-
mediated modes of action, and will briefly discuss Fab-mediated
mechanisms.
Fc-MEDIATED WORKING MECHANISMS
BLOCKADE OF ACTIVATING FcγR BY SATURATION AS A RESULT OF
HIGH IgG CONCENTRATIONS
Administration of IVIg greatly increases the total concentration
of IgG in the recipients’ plasma and extracellular fluid, and with
such an increase, more FcγRs may be bound by circulating non-
complexed IgG, thereby saturating the FcγRs and making them
less available for auto-antibodies in oligo- or polymeric complex
with their (auto)antigen. The idea that especially the low-affinity
FcγRs can be blocked by their monomeric ligand in vivo may at
first hand seem surprising, but it has been shown in the past that
also low-affinity receptors bind monomeric IgG (77), indicating
that some “low-affinity” FcγRs are not so low-affinity, and maybe
should be better named “medium-affinity,” especially in the case
of FcγRIIa and FcγRIIIa (38). Greatly increasing the concentra-
tion of monomeric IgG above the normal plasma levels may shift
the equilibrium toward a situation in which too many FcγRs are
occupied for proper functioning – which may in part explain the
immunomodulatory actions of IVIg under some of the condi-
tions for which IVIg is used. Saturation of activating FcγRs was
one of the first theories that was formulated to explain the work-
ing mechanism of IVIg (2), and this “classic” mechanism has for
a long time been assumed as the most plausible explanation for
the effect of IVIg in ITP (23, 78). Circumstantial evidence for
this theory derives from observations that IgG preparations with
increased affinity for FcγRs appear to have an increased effect (6,
79), and that in all diseases in which an immunomodulatory effect
is wanted, high doses of IVIg are needed. Nevertheless, there is no
formal proof for this concept, and although it has never been dis-
proven, focus has shifted away from this theory as other explaining
theories arose.
UPREGULATION OF THE INHIBITORY FcγRIIb AS A RESULT OF
SIALYLATED IgG-Fc
Over the past decade, the prevailing theory for the working mech-
anism of IVIg in most immunomodulatory situations has become
that IVIg induces an upregulation of the inhibitory FcγRIIb on
effector cells. More specifically, a fraction of IVIg, i.e., the IgGs
containing a sialic acid sugar residue at the end of the N-linked
glycosylation site at Asn297, would be responsible for this effect
by binding to SIGNR1 (mouse), or its human ortholog DC-
SIGN, inducing various signaling cascades ultimately leading to
the upregulation FcγRIIb. This theory has recently been excellently
reviewed in Ref. (80). However, the major problem with this theory
is that many findings could not be reproduced by other research
groups. For instance, we have recently found that FcγRIIb is not
upregulated in human macrophages in response to IVIg, but nev-
ertheless, these macrophages respond very well to IVIg treatment,
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being inhibited in phagocytosis (79). The role of FcγRIIb in ITP
treatment by IVIg was also questioned in mouse studies (81). Sim-
ilarly, we found that IgG-Fc sialylation was not important for the
effect of IVIg on human macrophages (79), and many groups
have recently published evidence that IgG-Fc sialylation of IVIg is
not required for the immunomodulatory effects (82–85). As men-
tioned before, even the binding of sialylated IgG-Fc to DC-SIGN
could not be reproduced (33). Furthermore, essentially all the evi-
dence supporting this theory derives from murine studies, which
may not be translated to the human situation, as mice and humans
extensively differ in FcγR expression. Many of the murine studies
describing this theory for instance use a model for arthritis, but
IVIg has never proven to be a useful therapy in treating arthritic
patients (86–88).
On the other hand, glycosylation may still be important, influ-
encing the binding affinity IgG molecules to the various FcγRs. For
instance, the binding affinity of FcγRIIIa is undoubtedly influ-
enced by the level of fucosylation of the Fc-domain of IgG, a
notion that may help to develop new, afucosylated IgG treatment
options (89, 90). An important question will be whether the anti-
inflammatory properties are directly influenced by afucosylated
IgG or IgG otherwise modified in their glycosylation status.
INCREASED CLEARANCE OF PATHOGENIC ANTIBODIES BY
SATURATION OF THE NEONATAL FcR
FcRn is a receptor expressed by human endothelial cells to recycle
plasma IgG, extending its half-life in the circulation (91, 92); satu-
rating this “rescue-receptor” with a high dose of IVIg may shorten
the half-life of all IgG including harmful auto-antibodies. Interest-
ingly, for a number of diseases in which IVIg therapy is beneficial,
plasmapheresis, aiming to remove pathogenic auto-antibodies by
replacing the patients’ plasma with donor plasma is also a good
option. This is for instance the case in Guillain Barre syndrome
(93, 94). On the other hand, plasmapheresis is not effective in ITP
(95, 96), and so apparently, rapid removal of auto-antibodies is
not effective in ITP, suggesting that the effect of IVIg in ITP must
be exerted in a different way.
BALANCE FROM PRO- TO ANTI-INFLAMMATORY REACTIVITY BY
MODULATING DENDRITIC CELLS
Recent data have confirmed the expression of FcγRII isoforms,
including FcγRIIb (97, 98) on dendritic cells (DCs), which may
help to explain the subsequent steps in which inhibition of
autoantibody release by B-cells, inhibition of T-helper (Th)1
and Th17 differentiation, and enhancement of CD4+FoxP3+
regulatory T cells (Treg), helps to modulate certain unwanted
(auto)inflammatory responses. IVIg may be able to reset the bal-
ance at the level of DCs, involving not only the classical IgG
receptors but also non-classical lectin-like surface molecules, as
has been repeatedly proposed during the last decade (33, 99). We
should emphasize that the relevance of such mechanisms and non-
classical IgG receptors remain to be shown in humans for the
IVIg-associated effects for immunomodulation.
REDUCING RESPONSES TO IFN
A recent report showed an increased expression of type I inter-
feron response genes in ITP patients, which was rapidly reduced
in patients after receiving IVIg, leading to decreased expression
of FcγRIII on monocytes, thereby altering the balance between
activating and inhibiting FcγRs (100). The relevance of interfer-
ons in such responses is unclear, as interferon response genes have
been found in various diseases, among which is SLE, and some-
times independent of clear-cut reaction to treatment and clinical
response to therapy (101, 102).
Inhibition of the complement cascade
Inhibition of the complement cascade by sequestering comple-
ment away from the deposited auto-antibodies as suggested in
dermatomyositis (103). On the other hand, with the recent insight
that IgG is only able to activate complement by means of gener-
ating hexamers, and not as single molecules or dimers (104), it
is less likely that complement scavenging roles can realistically be
involved in the anti-inflammatory IVIg-mediated effects.
Fab-MEDIATED WORKING MECHANISMS
NEUTRALIZATION OF AUTO-ANTIBODIES BY ANTI-IDIOTYPE Abs
One of the first explanations for the anti-inflammatory effect of
IVIg was that there are anti-idiotypic antibodies present in the
IVIg that neutralize the pathogenic auto-antibodies. This theory
is often claimed but to our knowledge has only been proven to
effectively explain the anti-inflammatory potential of IVIg in the
case of neutralizing antibodies to coagulation factor VIII, which
could be inhibited by anti-idiotypic antibodies in IVIg (105).
NEUTRALIZATION OF ENDOGENOUS CHEMOKINES, INFLAMMATORY
CYTOKINES, AND APOPTOSIS-INDUCING MOLECULES
Apart from the known microbial antigen-specific binding prop-
erties, IgG preparations also contain neutralizing and clearance-
enhancing antibodies that may switch a proinflammatory trigger
into an anti-inflammatory condition. This suggests that healthy
individuals from which plasma is collected and pooled for ther-
apeutic IgG preparations already contain autoreactive “natural”
antibodies at low levels in their blood. The infusion of such
natural antibodies into the patient may be sufficient to reset
certain diseases by the cross-reactive capacity of such natural
“auto”antibodies (106–110).
ROLE OF Fc-GAMMA RECEPTORS IN SHAPING THE IMMUNE
RESPONSE IN RELATION TO THE POTENTIAL ACTIONS OF
IVIg
Clearly, the different genetic FcγR variants may not only be a
risk factor for the development of some auto-immune diseases
but may possibly also influence the efficacy of treatment of these
diseases by IVIg. Indeed, some SNPs can be overrepresented in
Kawasaki disease (KD) patients that respond well to IVIg therapy,
but not in the non-responders. Among KD patients, patients who
respond well to IVIg have been reported to more often carry the
promoter polymorphism 2B.4 in FCGR2B and the FcγRIIIb-NA1
when compared to non-responders (111, 112). In both these cases,
the balance between activating and inhibitory receptor signaling is
altered. A shift toward the inhibitory side of the balance increases
the efficacy of IVIg treatment, while a shift toward the activat-
ing side shows the opposite effect. Connections of IVIg efficacy
in KD and/or other auto-immune diseases with other polymor-
phisms or CNV in FcγR have not been found to date. Given the
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FIGURE 4 |The different ways of how IVIg may influence an immune
response involving (auto)-antibodies by interfering with the function of
the different FcγRs on various cell types. (A) dendritic cells (DCs) play a
major role in the initiating phase of an antibody response, and expression and
function of different FcγRs on these cells may influence this response in
several ways. For instance, ligation of FcγRIIa on DCs has been shown to
influence the cytokine secretion by DCs in response to various TLR ligands,
promoting Th17 responses (98). Furthermore, expression of FcγRIIa on
myeloid DCs was recently shown to be downregulated by IVIg in an IL-33
dependent manner, which resulted in a Th2 cytokine response (97). As the
co-stimulatory signals derived from DCs determine T cell function, they are
ultimately important in shaping an antibody response, as well as the extent of
generating a neutrophil-driven response. T cells themselves are crucial in
determining the differentiation of most B-cells necessary for the antibody
response, but are not known to express any classical FcγRs or other IgG
receptors themselves, suggesting that they may be influenced by IVIg in
indirect ways only. (B) Differentiation of B-cells into antibody producing cells
is a major component of an (auto)-antibody response, and involves somatic
hypermutation, class switch recombination and plasma cell differentiation.
B-cells express high levels of FcγRIIb, and ligation of this receptor has been
shown to dampen B-cell receptor signaling. Recently, it was proposed that
also FcγRIIc is expressed on B-cells in some individuals, and may influence
the immune response in vaccination settings, although it appears that the
expression of FcγRIIc on B-cells is very limited if present at all, especially
when compared to expression of FcγRIIb (see also Figure 3B). (C) Once an
(auto)-antibody is formed, innate effector cells such as neutrophils are
determinants of tissue damage at the site of deposited immune complexes
by release of toxic components such as reactive oxygen species or proteases.
Neutrophils express FcγRIIa and FcγRIIc in some individuals, which can
contribute to tissue damage and inflammation, and may be influenced by
IVIg. Following the afferent immunological phase, the effector phase of
activated neutrophils may be in part driven by the presence of certain Th
subsets. The “inflammation-promoting” Th17 activity may be counterbalanced
by Tregs inducing immunosuppressive properties by TGF-β1 as indicated by
expression of neutrophil IL-10 and IL-6, indoleamine 2,3-dioxygenase (IDO),
heme oxygenase-1, and “suppressor of cytokine signaling-3” (SOCS3) (113),
although the production of these cytokines by human neutrophils remains
controversial. (D) In case of natural or therapeutic antibody responses against
cellular targets, these targets can be eliminated by cells of the innate immune
system, for instance through antibody-dependent phagocytosis by
macrophages, or antibody-dependent cellular cytotoxicity by NK cells (or
monocytes and neutrophils). These responses are mediated by FcγRs on
these effector cells, which could be influenced by IVIg in a direct way, i.e.,
saturating activating FcγRs by binding to them, or in a more indirect way as a
result of upregulation of the inhibitory FcγRIIb on effector macrophages
(discussed in the text).
growing number of diseases in which IVIg therapy is success-
fully used and the number of possible working mechanisms that
involve FcγR, it does not seem unlikely that more such connec-
tions exist. The ways in which IVIg may interact with FcγRs to
exert its immunomodulatory actions are multiple, since many dif-
ferent FcγRs are expressed by different immune cells. An overview
of the potential interactions is given in Figure 4. One special case
is the FcγRIIc, discussed in more detail below.
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FcγRIIc AS COMMON DENOMINATOR IN TIPPING PRO- OR
ANTI-INFLAMMATORY BALANCES?
As mentioned above, a SNP in exon 3 of FCGR2C determines
whether or not individuals can express FcγRIIc at all (5). Although
expression on NK cells is low, it has been shown to be capa-
ble of inducing killing of target cells in a redirected ADCC assay
(5). We could also detect FcγRIIc expression on neutrophils and
monocytes in individuals with an ORF allele (Figure 3A) (4).
When investigating surface FcγRIIc expression on monocyte-
derived macrophages skewed to either M1 or M2 phenotype, the
M-CSF-cultured cells were clearly expressing FcγRIIc (Figure 3C).
Surprisingly, a recent report also found FcγRIIc expression
on B-cells (22). Upon transfection into a murine B-cell line, the
co-ligation of FcγRIIc with the BCR resulted in enhanced and
more sustained tyrosine phosphorylation of the key B-cells sig-
naling components Syk and BLNK. In contrast, the engagement
of FcγRIIb with the BCR and its activation caused a reduced level
of Syk and BLNK phosphorylation. Antibodies generated upon
immunization in this transgene mouse model were found to be
enhanced, coinciding with a higher level of B-cell activation (22).
In a cohort of about 300 individuals of unknown ethnicity the lev-
els of Ab against a neoantigen (Anthrax protein) were tested (22).
At the earliest time points in the vaccine study donors homozy-
gous for the FCGR2C-ORF allele [i.e., two alleles (n= 11)] showed
higher Ab levels at 4 weeks (p< 0.02) but not any longer at 8 weeks
(22). The more common single-ORF donors were not included.
Although interesting, direct proof of FcγRIIc expression in
human B-cells is lacking, as the protein was only specifically
detected in EBV-transformed B-cell lines (22). Stainings with an
antibody detecting both FcγRIIb and FcγRIIc showed a difference
between Stop and ORF donors (22), suggesting some expression
of FcγRIIc in primary and memory B-cells. However, we per-
formed similar stainings in a much larger cohort and did not detect
such differences. Hence, we must conclude that the expression of
FcγRIIc on primary B-cells is at most marginal if present at all.
In fact, the myeloid expression on macrophages and DCs of
FcγRIIc may be held responsible for the earlier peak in Ab genera-
tion in FCGR2C-ORF-positive donors. Not only the macrophage
as effector mechanism in immune responses could be relevant for
adaptive immunity including Ab generation but also the affer-
ent part of adaptive responses may be involved, as may also be
suggested for FcγRIIc-expressing human DCs in FCGR2C-ORF
individuals. Thus, we hypothesize that FcγRIIc may be a sub-
tle but relevant genetic factor in the fine balance between health
and disease, including the way the immune response will shape
the adaptive repertoire as indicated by the immunization studies
mentioned above (22) (Figure 4, overview).
CONCLUSION
The Fc-gamma Receptors constitute the major receptors for
human IgG. There may be low-affinity receptors with lectin-like
binding properties that have been suggested to bind a fraction
of IgG depending on IgG glycosylation, such as sialylation, but
definite proof awaits further study. The beneficial effects of sia-
lylated IVIg in mice are model-dependent, and evidence that
sialylation of IgG plays a role in humans has not been generated
thus far. Evidence for a prominent role of DC-SIGN in mediating
the anti-inflammatory activity of IVIg in humans is also lacking.
Thus, clinical application of sialic acid-enriched IVIg in humans
is supposed not to be superior to conventional IVIg. In fact, the
classically proposed mechanism of IVIg saturating the FcγRs still
appears to be the most logical explanation for the immunomodu-
latory effects in at least some diseases for which it is indicated, for
instance in ITP. However, different mechanisms may be at work in
other inflammatory diseases for which IVIg is used, and it is not
unlikely that different mechanisms act in concert. Fab-mediated
IVIg actions may be relevant for some indications, but clinical
studies have in the past ruled out Fab-mediated mechanisms to be
important for ITP. Knowledge on whether the immunomodula-
tory effect of IVIg for a given indication is Fc- or Fab-mediated
may become very important if alternative (i.e., not donor-derived)
sources of IgG are to be used in the future. When the effects of
IVIg are Fc-mediated, the polyclonal aspect of IVIg is clearly not
important, and recombinant IgG preparations may suffice, which
can then be specifically modified to enhance function. On the
other hand, for indication in which the effects are Fab-mediated,
the polyclonality is likely to be very important, and recombinant
preparations can only be successful if the relevant clones can be
identified and expanded for therapeutic IgG production. However,
the results of the ITP studies preclude further clinical trials with
Fab-only or Fc-only preparations for other indications, as this may
withhold patients a currently effective therapy – which clearly is
unethical. Hence, it will remain difficult to determine the relative
importance of Fab and Fc for indications other than ITP in the
human situation.
Although the sialylation of IgG-Fc appears not to be relevant
for its immunomodulatory effect, the glycosylation status of IgG
may still be important for its function, as the properties of IVIg
preparations can for instance be dependent on the level of fuco-
sylation, having effect on the binding affinity to FcγRs. Further
studies will help to resolve the effects of the different glycosylation
moieties of IgG-Fc on the interactions with the various receptors
for IgG-Fc, and the relevance of these interactions for IVIg func-
tion. Finally, FcγRIIc is one novel activating IgG receptor that may
add to tip the balance of immune responses, which needs further
in-depth study, using proper detection methods to obtain evidence
by genotyping and biochemistry.
Concluding, an enormous increase in insight has been gen-
erated during the last decade that may help to improve IgG
therapy,either as supplement or anti-inflammatory approach. Fur-
ther studies related to glycosylation may be highly relevant in this
respect, but the immunomodulatory effects of IVIg seem not to
be determined by the level of sialylation as studied in-depth over
the last decade.
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